Abstract
Hypoxic tumors are associated with poor clinical outcome for multiple types of human cancer. This may be due, in part, to hypoxic cancer cells being resistant to anticancer therapy, including radiation therapy, chemotherapy, and targeted therapy. Hypoxia inducible factor 1, a major regulator of cellular response to hypoxia, regulates the expression of genes that are involved in multiple aspects of cancer biology, including cell survival, proliferation, metabolism, invasion, and angiogenesis. Here, we review multiple pathways regulated by hypoxia/hypoxia inducible factor 1 in cancer cells and discuss the latest advancements in overcoming hypoxia-mediated tumor resistance.
| Original language | English |
|---|---|
| Pages (from-to) | 253-264 |
| Number of pages | 12 |
| Journal | Cancer Management and Research |
| Volume | 7 |
| DOIs | |
| State | Published - Aug 12 2015 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Hif-1 apoptosis cancer chemoresistance signaling
Fingerprint
Dive into the research topics of 'Progress toward overcoming hypoxia-induced resistance to solid tumor therapy'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver